CAR T-Cell therapy trial for lymphoma pulled before it started
NCT ID NCT06313996
First seen Mar 21, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This study was designed to compare a CAR T-cell therapy called Liso-cel against standard treatments for adults with follicular lymphoma that had come back or stopped responding to previous therapy. The trial was a large Phase 3 study planned at multiple hospitals worldwide, but it was withdrawn before any patients were enrolled. No results or safety data were collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lisocabtagene maraleucel (Liso-cel, also known as BREYANZI)
What this could lead to
If successful, this could offer a more effective treatment option for people with follicular lymphoma that has returned or not responded to prior therapy.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. CAR T-cell therapies can cause serious side effects like cytokine release syndrome and neurological problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.